These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 21262133)
1. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment. Yee SB; Hatkin JM; Dyer DN; Orr SA; Pitt ML Comp Med; 2010 Dec; 60(6):461-8. PubMed ID: 21262133 [TBL] [Abstract][Full Text] [Related]
2. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. Leffel EK; Bourdage JS; Williamson ED; Duchars M; Fuerst TR; Fusco PC Clin Vaccine Immunol; 2012 Aug; 19(8):1158-64. PubMed ID: 22695155 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. Kammanadiminti S; Patnaikuni RK; Comer J; Meister G; Sinclair C; Kodihalli S PLoS One; 2014; 9(9):e106393. PubMed ID: 25226075 [TBL] [Abstract][Full Text] [Related]
4. Transient lipopolysaccharide-induced resistance to aerosolized Bacillus anthracis in New Zealand white rabbits. Yee SB; Dyer DN; Twenhafel NA; Pitt ML Comp Med; 2013 Jun; 63(3):252-61. PubMed ID: 23759528 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619 [TBL] [Abstract][Full Text] [Related]
6. Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen. Henning LN; Carpenter S; Stark GV; Serbina NV Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133571 [TBL] [Abstract][Full Text] [Related]
7. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits. Corey A; Migone TS; Bolmer S; Fiscella M; Ward C; Chen C; Meister G Toxins (Basel); 2013 Jan; 5(1):120-38. PubMed ID: 23344456 [TBL] [Abstract][Full Text] [Related]
8. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Mohamed N; Clagett M; Li J; Jones S; Pincus S; D'Alia G; Nardone L; Babin M; Spitalny G; Casey L Infect Immun; 2005 Feb; 73(2):795-802. PubMed ID: 15664918 [TBL] [Abstract][Full Text] [Related]
9. Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment. Comer JE; Ray BD; Henning LN; Stark GV; Barnewall RE; Mott JM; Meister GT Clin Vaccine Immunol; 2012 Sep; 19(9):1517-25. PubMed ID: 22837095 [TBL] [Abstract][Full Text] [Related]
11. Antibiotics cure anthrax in animal models. Weiss S; Kobiler D; Levy H; Pass A; Ophir Y; Rothschild N; Tal A; Schlomovitz J; Altboum Z Antimicrob Agents Chemother; 2011 Apr; 55(4):1533-42. PubMed ID: 21263056 [TBL] [Abstract][Full Text] [Related]
12. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178 [TBL] [Abstract][Full Text] [Related]
14. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Heine HS; Bassett J; Miller L; Hartings JM; Ivins BE; Pitt ML; Fritz D; Norris SL; Byrne WR Antimicrob Agents Chemother; 2007 Apr; 51(4):1373-9. PubMed ID: 17296745 [TBL] [Abstract][Full Text] [Related]
15. Development of an inhalational Bacillus anthracis exposure therapeutic model in cynomolgus macaques. Henning LN; Comer JE; Stark GV; Ray BD; Tordoff KP; Knostman KA; Meister GT Clin Vaccine Immunol; 2012 Nov; 19(11):1765-75. PubMed ID: 22956657 [TBL] [Abstract][Full Text] [Related]
16. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Peterson JW; Comer JE; Baze WB; Noffsinger DM; Wenglikowski A; Walberg KG; Hardcastle J; Pawlik J; Bush K; Taormina J; Moen S; Thomas J; Chatuev BM; Sower L; Chopra AK; Stanberry LR; Sawada R; Scholz WW; Sircar J Infect Immun; 2007 Jul; 75(7):3414-24. PubMed ID: 17452469 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Biron B; Beck K; Dyer D; Mattix M; Twenhafel N; Nalca A Antimicrob Agents Chemother; 2015 Apr; 59(4):2206-14. PubMed ID: 25645849 [TBL] [Abstract][Full Text] [Related]